

The Examiner is invited to telephone applicants' representatives regarding any matter that may be handled by telephone to expedite allowance of the pending claims.

Respectfully submitted,

Karen Mangasarian

James F. Haley, Jr. (Reg. No. 27,794)
Karen Mangasarian (Reg. No. 43,772)
Attorneys for Applicants
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000

I hereby certify that this
correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
addressed to:
Commissioner for Patents, P.O. Box 2327
ARLINGTON, VA 22202 on

MAY 20, 2002
William Bailey
Name of person signing

William Bailey
Signature of person signing

APPENDIX OF CLAIM AMENDMENTS

2. (Amended) A method for improving the angiogenic inductive activity of a morphogenic protein selected from the group consisting of OP-2, OP-3, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, OP-1 (BMP-7), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, DPP, Vg-1, Vgr-1, 60A protein, NODAL, UNIVIN, SCREW, ADMP, NEURAL, COP-5, COP-7 and an amino acid sequence having at least 70% amino acid sequence homology with residues 330-431 of SEQ ID NO: 2 in a mammal by coadministering with the morphogenic protein an effective amount of a morphogenic protein stimulatory factor, wherein the amino acid sequence has angiogenic activity.

6. (Twice amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein is [comprises an amino acid sequence] selected from the group consisting of BMP-3, BMP-4, BMP-5, BMP-6, OP-1 (BMP-7), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, COP-5, [and] COP-7 and an amino acid sequence having at least 70% amino acid sequence homology with residues 330-431 of SEQ ID NO: 2 [an amino acid sequence variant thereof], wherein the amino acid sequence [variant] has angiogenic activity.

8. (Twice amended) The method according to claim 7, wherein the monomeric species is selected from the group consisting of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and [amino acid sequence variants thereof] an amino acid sequence having at least 70% amino acid sequence homology with residues 330-431 of SEQ ID NO: 2, wherein

the amino acid sequence [variant] has angiogenic activity.

10. (Twice amended) The method according to claim 9, wherein the dimeric species comprises a polypeptide selected from the group consisting of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and [amino acid sequence variants thereof] an amino acid sequence having at least 70% amino acid sequence homology with residues 330-431 of SEQ ID NO: 2, wherein the amino acid sequence [variant] has angiogenic activity.

13. (Twice mended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting of acidic fibroblast growth factor (aFGF), basic fibroblast growth factor FGF (bFGF), transforming growth factor- β (TGF- β), transforming growth factor- α (TGF- α), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), endothelial cell growth factor (ECGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), platelet activating factor (PAF), interleukin-8 (IL-8), placental growth factor (PGF), proliferin, B61, soluble vascular cell adhesion molecule-1 (SVCAM-1), soluble E-selectin, ephrin, 12-hydroxyeicosatetraenoic acid, tat protein of HIV-1, angiogenin, prostaglandin [and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein].

14. (Twice amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound

selected from the group consisting of basic fibroblast growth factor (bFGF), platelet derived transforming growth factor- β 1 (TGF- β 1) [and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein].

15. (Twice amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of basic fibroblast growth factor (bFGF) [and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein].

16. (Twice amended) The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of platelet derived transforming growth factor- β 1 (TGF- β 1) [and amino acid sequence variants thereof, wherein the amino acid sequence variant of the morphogenic protein stimulatory factor improves the angiogenic inductive activity of the morphogenic protein].